Changes in HbA1c and hypoglycemic episodes in type 1 diabetes patients after switching to insulin glargine U300: Pilot study

Marina Gradišer; Maja Cigrovski Berković; Ines Bilić-Ćurčić

doi:10.1016/j.diabres.2017.03.036

Changes in HbA1c and hypoglycemic episodes in type 1 diabetes patients after switching to insulin glargine U300: Pilot study

Diabetes Res Clin Pract. 2017 Jul:129:144-147. doi: 10.1016/j.diabres.2017.03.036. Epub 2017 May 9.

Authors

Marina Gradišer¹, Maja Cigrovski Berković², Ines Bilić-Ćurčić³

Affiliations

¹ Internal Medicine Ward, General Hospital Čakovec, Čakovec, Croatia.
² Department for Endocrinology, Diabetes and Metabolism, University Hospital Centre "Sestre Milosrdnice", Zagreb, Croatia.
³ Department of Pharmacology, Faculty of Medicine, University J.J. Strossmayer, Osijek, Clinical Hospital Center Osijek, Croatia. Electronic address: ibcurcic@mefos.hr.

PMID: 28527305
DOI: 10.1016/j.diabres.2017.03.036

Abstract

We included diabetes type 1 (T1DM) patients with suboptimal glycemic control on morning application glargine (I-Glar) U100, switching them to U300. After six months improvement in HbA1c was observed, while hypoglycemic episodes decreased. Switch from I-Glar U100 to U300 could be a good therapeutic option for that subset of patients.

Keywords: Glargine U100; Glargine U300; Glycemic control; Hypoglycemia; T1DM.

MeSH terms

Child
Diabetes Mellitus, Type 1 / drug therapy
Female
Glycated Hemoglobin / metabolism*
Humans
Hypoglycemia / drug therapy*
Hypoglycemic Agents / therapeutic use*
Insulin Glargine / therapeutic use*
Insulin, Long-Acting / therapeutic use*
Male
Pilot Projects

Substances

Glycated Hemoglobin A
Hypoglycemic Agents
Insulin, Long-Acting
Insulin Glargine